Document Detail

Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spontaneous reporting of cardiomyopathy.
MedLine Citation:
PMID:  19240086     Owner:  NLM     Status:  MEDLINE    
A recent literature review linked norepinephrinergic stimulation to alterations in cyclic adenosine monophosphate (cAMP)-mediated signaling in cardiac myocytes and suggested that this might contribute to the pathological mechanisms that lead to chamber enlargement and hypocontractility, which are seen in dilated cardiomyopathy. This accompanies a large body of literature linking cardiac sympathetic outflow activation in early heart failure with progressive myocyte deterioration. As the mode of action of a number of antidepressants involves the inhibition of neuronal norepinephrine reuptake to varying degrees, this study was conducted to assess whether such agents might be associated with disproportionate reporting of cardiomyopathy. Limited data exist specifically examining the association between the antidepressant use and the cardiomyopathy. Using a data mining algorithm (DMA), we quantitatively investigated the association between antidepressant agents that predominantly exert their effects through inhibiting neuronal norepinephrine reuptake (rather than serotonin) and cardiomyopathy. We retrospectively applied a Bayesian DMA, the Bayesian Confidence Propagation Neural Network, to the cumulative reports in the Food and Drug Administration Adverse Event Reporting System (through the fourth quarter of 2006) and World Health Organization Vigibase (through the second quarter of 2007) databases. A threshold of the posterior interval 95% lower limit > 0 was used to define a signal of disproportionate reporting with individual or groups of antidepressants and cardiomyopathy-related terms. The analysis suggested that there is no direct relationship between antidepressants with greater norepinephrine reuptake inhibitor activity (affinity for norepinephrine reuptake transporter or selectivity for norepinephrine versus serotonin) and reporting of cardiomyopathy. In contrast, an inverse correlation might exist with a higher number of cases identified with tricyclic antidepressants showing lower norepinephrine reuptake inhibition and the serotonin/norepinephrine reuptake inhibitors as well as with serotonin/ norepinephrine/slight dopamine reuptake inhibitor.
S Ratcliffe; M Younus; M Hauben; L Reich
Related Documents :
6376546 - Serotonin-immunoreactive neurons in the brain of the honeybee.
17917116 - Morphogenic signaling in neurons via neurotransmitter receptors and small gtpases.
19394356 - Protective actions of ovarian hormones in the serotonin system of macaques.
25348266 - Repeated administration of a synthetic cannabinoid receptor agonist differentially affe...
9564876 - Expression of estrogen receptor-beta messenger ribonucleic acid in oxytocin and vasopre...
7104766 - Postnatal development of monoamine content and synthesis in the cerebral cortex of rhes...
Publication Detail:
Type:  Journal Article     Date:  2009-02-24
Journal Detail:
Title:  Journal of psychopharmacology (Oxford, England)     Volume:  24     ISSN:  1461-7285     ISO Abbreviation:  J. Psychopharmacol. (Oxford)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-02     Completed Date:  2010-06-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907828     Medline TA:  J Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  503-11     Citation Subset:  IM    
Risk Management Strategy, Pfizer Global Research and Development, Sandwich, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic Agents / adverse effects*
Adverse Drug Reaction Reporting Systems
Antidepressive Agents / adverse effects*
Bayes Theorem
Cardiomyopathies / chemically induced*
Data Mining
Dopamine Uptake Inhibitors / adverse effects
Evidence-Based Medicine
Neural Networks (Computer)
Neurons / drug effects*,  metabolism
Norepinephrine / metabolism*
Retrospective Studies
Risk Assessment
Risk Factors
Serotonin Uptake Inhibitors / adverse effects
Reg. No./Substance:
0/Adrenergic Agents; 0/Antidepressive Agents; 0/Dopamine Uptake Inhibitors; 0/Serotonin Uptake Inhibitors; 51-41-2/Norepinephrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and ...
Next Document:  Lhermitte's sign, Electric shock sensations and high dose ecstasy consumption: preliminary findings.